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Abstract 
Assessments of diseases are usually performed by a combination of clinical 
symptoms, signs and objective measurements. Biochemical markers of inflammation 
are important in evaluation of treatment of acute and chronic diseases. In this thesis 
we have focused on two inflammatory diseases: acute radiation proctitis and 
rheumatoid arthritis. We examined established and new biomarkers, with focus on 
two closely related proteins, calprotectin (S100A8/S100A9) and S100A12 (EN-
RAGE). These and other biomarkers were compared to clinical symptoms and signs 
with the aim of defining their usefulness in monitoring the course of the diseases. 
Characterizing the changes induced by radiation therapy to the pelvic region showed 
incongruent time profiles in symptoms, histological scoring of inflammation and 
biochemical measurements. Compared to the examination before start of radiation 
therapy, biopsies from rectal mucosa showed a maximal inflammation at the first 
examination during radiation therapy, while symptoms were at the most intense 
towards the end of treatment. Vitamin E concentrations in blood were significantly 
lower during treatment but returned to normal within a month. Calprotectin and 
lactoferrin concentrations in stool samples increased during therapy and were the 
most promising biomarkers for radiation proctitis in our study. 
Development of an ELISA immunoassay for the quantification of S100A12 in blood 
showed that calcium concentration influenced the estimated S100A12 concentrations. 
Various experiments led to the conclusions that the antibodies used in this assay 
could only recognize S100A12 when calcium were above a threshold and that 
S100A12 were found in many molecular sized complexes (oligomers) in blood. 
S100A12 was found to bind to heparin and this will be further examined in the future.   
Calprotectin and CRP in blood correlated with disease activity of rheumatoid 
arthritis. S100A12 was associated with a more severe disease course in terms of 
extra-articular disease manifestations and the presence of cardiovascular disease. 
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S100A12 correlated with rheumatoid factor and anti-CCP and may thus be of 
prognostic value. 
In summary, radiation proctitis occurs in biopsies before symptoms are evident. This 
is important knowledge for studies with interventions to prevent development of late 
radiation enteropathy. Stool markers are at present the best suited objective means of 
assessing interventions. The quantification of S100A12 in blood samples are 
recommended to be done in serum samples, since both anticoagulants EDTA and 
heparin may influence conformational changes of S100A12 protein structure and 
hence the measured concentrations. The usefulness of S100A12 as a biomarker in 
rheumatoid arthritis and other inflammatory diseases warrants further examinations. 
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1. General introduction 
1.1 Biomarkers as indicators of disease activity 
The term biomarker will be used in this study to distinguish the measurement of an 
endogenous substance from clinical parameters related to disease processes. 
Biomarkers can be divided in groups related to common properties, like antibodies, 
cytokines, adhesion molecules, acute phase proteins (e.g. C-reactive protein, CRP) or 
leukocyte proteins (e.g. calprotectin and S100A12). Another classification is to use 
the biochemical nature of the molecules to define proteins, lipids or carbohydrates 
and compounds derived from these as the category, e.g. eicosanoids as lipid 
mediators in inflammatory processes. 
Some biomarkers can reflect disease activity by increased or decreased concentration. 
Other biomarkers are useful in differential diagnostics but not to monitor disease, e.g. 
rheumatoid factor (RF) in rheumatoid arthritis (RA). Biomarkers like RF and 
calprotectin may yield prognostic information in the individual patient, namely 
increased risk of future disease manifestations.   
If available, an ideal biomarker will be preferred to scoring systems of disease 
activity since they are objective means of evaluating pathology and treatment 
efficacy.  
The ideal biomarker should also be easily applicable for routine clinical purposes, 
stable in blood or stool samples, fluctuate with disease severity and normalize 
following successful therapy or recovery.  
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1.2 Leukocyte proteins in inflammation 
The rapidly responding innate immune system consists of: 1) physical and chemical 
barriers, e.g. epithelial surfaces; 2) phagocytes and natural killer cells; 3) blood 
proteins and 4) cytokines (1). The phagocytic cells are mainly the macrophages and 
polymorphonuclear neutrophil granulocytes (neutrophils), the latter being the most 
abundant type of circulating leukocytes and the major cell type mediating acute 
inflammatory responses to bacterial infections (1). The increase in plasma 
concentrations of several proteins, mostly synthesized in the liver as a systemic 
inflammatory response, is up-regulated by cytokines like tumour necrosis factor-α 
(TNF-α) and IL-6 (interleukin-6) (1). Cytokines are proteins secreted by the cells of 
innate and adaptive immunity as a response to microbes and other antigens. The same 
protein may be synthesized by many cell types, including endothelial cells and other 
tissue cells, and activate different effector cells to eliminate microbes and other 
antigens (1). This activation of leukocytes initiates up-regulation and secretion of 
various molecules. The up-regulation implies activation of genes, increased 
concentration of mRNA and protein synthesis. Inflammation is characterized by 
recruitment and activation of the leukocytes at sites of infection or tissue damage and 
extravasation of several plasma proteins (1). Circulating proteins include members of 
the complement system, coagulation factors, CRP and mannose-binding lectin. These 
are particularly important in the innate immune system (1). Examples of laboratory 
investigations related to inflammation are erythrocyte sedimentation rate (ESR), 
CRP, leukocyte count, platelets, fibrinogen, serum amyloid A, ferritin, α1-antitrypsin, 
complement factors, albumin and transferrin. The last two are found in decreased and 
the others in increased concentrations during inflammation (2).  
The proteins transferrin and lactoferrin are synthesized in leucocytes. They are carrier 
proteins of iron and prevent iron from catalyzing redox reactions during transport in 
the circulation (3). The most abundant cytosolic protein in phagocytic cells, 
calprotectin, has become a clinically useful biomarker in inflammatory bowel disease 
(IBD) when measured in stool samples (4-6). This is due to high concentration and 
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stability of calprotectin in stools and correlation of disease activity and leukocyte 
excretion in stools (7). Although not specific for IBD, fecal calprotectin 
measurements are useful in screening for organic bowel diseases, and monitoring 
disease activity of known IBD, thereby reducing the need for endoscopic 
examinations. Lactoferrin in stool samples is another leukocyte protein examined as a 
potential biomarker of intestinal mucosal inflammation (8-10). Granulocyte 
transmigration into the bowel lumen during radiation therapy was assessed by 
measurement of transferrin in stools of rats and found to be predictive of later 
radiation enteropathy (11). Both α1-antitrypsin and lactoferrin in stools have been 
evaluated as markers of disease activity of IBD (8;9).  
 
1.2.1 S100 proteins calprotectin (S100A8/A9) and S100A12 
Calprotectin was first called L1, Leukocyte protein candidate 1, as the first protein 
that might reflect granulocyte turnover in vivo (12). The name calprotectin was 
suggested when the protein was found to have antimicrobial properties (13). 
Calprotectin has a molecular mass of about 36 kilo Dalton (kDa) and consists of 
subunit polypeptide chains, L1 Heavy and L1 Light chains with molecular masses of 
about 13 and 8 kDa, respectively (14;15). The functional protein is referred to as 
calprotectin, since the subunits have not been reported to occur as free, individual 
proteins in vivo (16). The subunits L1 Heavy and L1 Light chains have identical amino 
acid sequences of MRP-14 and MRP-8 (17). Other groups have named subunits 
calgranulin A and B (18). Additional synonyms are listed by Ravasi et al (19). 
Calprotectin constitutes about 60% of the proteins in cytosol of neutrophils (20). 
Calprotectin is mainly found in cells of the monocyte-derived cell lineage, in 
peripheral neutrophils and monocytes (12;21) and macrophages in formalin-fixed and 
paraffin-embedded routine material (22;23). Other tissues and squamous type 
epithelia also express calprotectin (22;24). 
 16 
The term “S100 protein” was originally used to describe proteins that were “soluble 
in a 100% saturated solution with ammonium sulphate” (25). This family of proteins 
is one of the classes of Ca2+ -binding proteins that regulate the levels of cytosolic 
calcium concentration by being buffers, or acting as second messengers by altering 
their activities depending on the calcium concentration (26-28). They are members of 
the EF-hand superfamily of Ca2+ -binding proteins, of which more than 600 have 
been identified from the human genome (27). Twenty-one of at least 25 members of 
S100 proteins have their genes in a cluster located on human chromosome 1q21, and 
a nomenclature according to this position has been suggested (19;29). S100 proteins 
are proposed to have both intracellular and extracellular functions, supposedly as 
trigger or activator proteins; by contrast, other Ca2+ -binding proteins are considered 
to act mainly as buffers (26;28). The majority of S100 protein interactions are 
calcium-dependent (27). 
The three-dimensional, conformational state of S100 proteins are modulated by the 
calcium concentration, and S100 proteins form both homo- and hetero-dimers and 
larger complexes (26;27;30). Ca2+ -binding is responsible for changes in the global 
shape and charge distribution of S100A4, S100A6 and calprotectin (31-33).  
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Figure 1. Comparison of S100A6 structures in the apo (A) and 
calcium bound (B) states 
Molecular surface representation of the asymmetric unit of S100A6 (in the apo form , 
Protein Data Bank (PDB) http://www.rcsb.org/pdb/Welcome.do entry 1K9P and in calcium 
bound form PDB entry 1K96) coloured by electrostatic potential with the two forms of 
protein in the same orientation. Increasing saturation of negative and positive potential is 
represented by red and blue respectively. Location of different residues shows the 
conformational changes in the presence of calcium. 
The images are oriented with calcium binding loop on the top. The figure was created using 
Swiss-Prot Deep Viewer software (SPDV). The electrostatic potential was calculated by 
SPDV.  
Illustration made by Igor B. Bronstein, London. Printed with kind permission. 
 
Calprotectin is suggested to be a hetero-oligomer, consisting of one or more trimers 
(16;20;34). In the absence of calcium, recombinant S100A8 and S100A9 are thought 
to form stable heterodimers, while the oligomerization in the presence of calcium is 
discussed in the literature (35). Heterotetramer (S100A8/S100A9)2 was recently 
suggested as the functional state necessary for the formation of microtubules in yeast 
cells (36). Five different combinations of complexes were suggested to occur in 
extracts from carotid arteries with atherosclerosis (37).  
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Figure 2. Calprotectin 
Molecular surface representation of calprotectin coloured by electrostatic potential. 
Increasing saturation of negative and positive potential is represented by red and blue 
respectively. Location of different residues shows the conformational changes in the 
presence of calcium. 
The figure was created using SPDV. The electrostatic potential was calculated by SPDV.  
Illustration made by Igor B. Bronstein, London. Printed with kind permission. 
 
Non-covalently associated complexes of S100 proteins are considered a prerequisite 
for their biological functions in vivo. One example of this was studied by two 
independent groups, agreeing that complex formation of S100A8 and S100A9 was 
necessary for the binding of polyunsaturated fatty acids (PUFAs), e.g. arachidonic 
acid (AA) (38;39). If calcium concentrations were below a critical level the binding 
capacity was lost. One of the research groups induced complex binding of S100A8 
and S100A9 by zinc or copper instead of calcium, but these complexes had 
conformational differences from the calcium-induced protein complex and could not 
bind AA (40). A recently described clinical syndrome with recurrent infections, 
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hepatosplenomegaly, anemia and evidence of systemic inflammation was 
characterized by hyperzincaemia and hypercalprotectinaemia (41). Calprotectin was 
found to inhibit matrix metalloproteinases by sequestration of zinc (13;42).The 
antimicrobial activity of calprotectin was abolished by addition of zinc (43). S100A8 
and S100A9 alone had no antimicrobial activity (43). This may suggest that a high 
affinity zinc binding site is generated by complex formation between the subunits. 
The affinity for zinc is thought to be high enough for calprotectin to reduce the zinc 
concentration sufficiently to inhibit microbial growth.  
Calprotectin and a more recently described member of the S100 family, S100A12, 
have many functions related to inflammation (26;44;45). S100A12 was first called p6 
(46) due to an estimated molecular weight of 6.5 kDa. It constitute 5-8 % of cytosolic 
proteins of neutrophils (in human, porcine or rabbit) (46-48). S100A12 was found to 
be a ligand for the receptor for advanced glycation end products (RAGE) (49), and 
therefore called EN-RAGE (extracellular newly identified RAGE binding protein, 
EN-). Different research groups have assigned various names for this protein: 
calgranulin C, calcium binding protein in amniotic fluid-1 (CAAF-1), MRP-6, CGRP 
(19;50;51).  
The concentrations of Ca2+, Zn2+ and Cu2+ were shown to influence the three-
dimensional structure (conformational state) of S100A12 (52-54). Calcium and 
probably other ions, determine whether S100A12 is found as monomers, dimers or 
oligomers. In signal transduction of inflammation, the concentration of the Ca2+ ions 
in the milieu around S100A12 is proposed to be the determinant of whether S100A12 
participate in a signal cascade or not. The hexamer is suggested to be the form that 
interacts with RAGE (30). Two different conformational states of the hexamer are 
shown in fig. 3 
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Figure 3. Structural organisation of S100A12 oligomer 
The diagrams A and B illustrates how the two subunits of S100A12 (PDB entry 1E8A) 
(coloured by blue and green to differentiate the subunits in A) makes extensive surface 
contacts. Two monomers are firmly holding each other. The diagrams C (PDB entry 1GQM) 
and D (PDB entry 1ODB) illustrates how the dimer associate into two types of oligomers. 
Interactions between subunits in the hexamer (C) are mediated by the addition of six 
calcium atoms. Images are shown in a semitransparent surface representation. The route of 
assembly is purely illustrative and represent assembly of the oligomeric particles in crystal. 
The figure was made using the program PyMol.  
Illustration made by Igor B. Bronstein, London. Printed with kind permission. 
 
 
1.2.2 Endothel, RAGE and atherosclerosis 
Calprotectin and S100A12 has mainly been found in monocytes and neutrophils (19-
22;45;46), important effector cells of immune responses. Recruitment of leukocytes 
from the circulation is initiated by the binding of cytokines (and other molecules with 
chemotactic properties) to endothelial cell heparan sulfate glycosaminoglycans, 
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which activate the rolling leukocytes and convert the integrins to a high-affinity state 
(1). This is followed by firm adhesion of leukocytes, which then migrate through the 
endothelium. Both calprotectin and S100A12 have chemotactic properties (45;55-57). 
Calprotectin and S100A9 were found to bind to endothelial cells via the heparan 
sulfate proteoglycans (58), and S100A9 had a high affinity for heparin. 
Immunohistochemical studies found S100A8 and/or S100A9 in macrophages, foam 
cells, extracellular matrix and in early and advanced calcified deposits of 
atherosclerotic vessels (37). These research groups suggest that the presence of 
S100A8 and S100A9 may reduce oxidative damage (37;58). On the other hand, 
calprotectin in high concentrations (like those seen in plasma during bacterial 
infections) induced apoptosis in vitro in all cell types tested so far (59). 
In contrast to the suggested protective anti-oxidant function of calprotectin (37;58), 
endothelial cells showed increased release of IL-6, soluble intercellular adhesion 
molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) after 
stimulation with calprotectin, but not if incubated with either S100A8 or S100A9 
alone (60). However, this effect was only found after preincubation with advanced 
glycation end products (AGE). AGE are glycosylated lipids and proteins that are 
found in increased concentrations with increasing age and in patients with diabetes 
mellitus, atherosclerosis and other chronic diseases (61;62). The authors hypothesized 
from their observations that S100A8/S100A9 binds to various cell receptors 
depending on the surrounding milieu, leading to differentiated downstream signalling 
(60). Calprotectin concentrations increased almost 100-fold when measured in 
plasma before and within minutes after finishing marathon-running (63). Neutrophil 
count increased only 3.4-fold in the same individuals’ samples. The amount of 
calprotectin per neutrophil were in the same range after 30-km running as in healthy 
controls, and calprotectin in plasma increased 20-fold (63). Even though some of this 
increase  might be caused by crushing of leukocytes, the finding supports two in vitro 
experiments describing secretion of calprotectin from human neutrophils (64;65). The 
significance of the increased calprotectin concentration is unknown. The publications 
discussed above suggest antioxidant functions as well as proinflammatory effects on 
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endothelial cells under some conditions. Hypoxia and tissue damage caused by the 
running can be regarded as proinflammatory events.  
S100A12 was found in macrophages in autopsy specimens from coronary arteries in 
a study of sudden cardiac death (66). The non-diabetic subjects had less macrophage 
infiltrate in their arteries than the diabetic subjects. In sections from diabetes mellitus 
type 2 more healed infarcts and cardiomegaly was found, while type 1 diabetic 
subjects had low rates of healed infarcts and acute thrombosis. The autoimmunity 
aspect of type 1 diabetes was speculated to be involved in the observed differences. 
The research group that first described the protein as a ligand for RAGE (49) found 
that S100A12: 1) increased the expression of ICAM-1 and VCAM-1 adhesion 
molecules on human endothelial cells; 2) increased the generation of TNF-α, IL-1β 
and IL-2 from leukocytes; and 3) acted chemotactic for macrophages. The interaction 
of S100A12 with RAGE was also shown by Moroz et al (30). At present, the 
prevailing perception is that RAGE acts as a receptor recognizing patterns of three-
dimensional structures, such as β-sheets and fibrils, rather than specific amino acid 
sequences (i.e. primary structure) (61;62). This explains that RAGE can be activated 
by many ligands. The ligand-receptor interaction induce a sustained post-receptor 
signal which include activation of p21ras, MAP kinases and the NF-κB pathway 
(61;62). Blocking of RAGE by the soluble fragment of the receptor (sRAGE) can 
attenuate inflammatory responses in many animal models (49;61), but it does not 
completely abolish these, probably because the ligands of RAGE can interact with 
other cell surface molecules or receptors (58;61;62). Application of sRAGE in the 
animal models showed reduced late complications in diabetes, prevention of micro- 
and macrovascular diseases and improved the outcome of experimental colitis 
(49;61).  
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1.2.3 Measurements of calprotectin and S100A12 
The clinical application of calprotectin and S100A12 as biomarkers of inflammatory 
diseases and infections have been suggested in many disease states (44;59;67). Up-
regulation of genes indicates a first step towards synthesis of a functional protein. 
Gene expression of blood mononuclear leukocytes showed up-regulation of mRNA 
for S100A8 and S100A12 proteins (and other substances) in rheumatoid arthritis’ 
patients (68;69). Patients with Kawasaki vasculitis had up-regulated gene expression 
for S100A8, S100A9 and S100A12 during the acute phase of the disease (70;71). In 
the study by Abe et al. (70), plasma concentrations of calprotectin were estimated by 
two different enzyme-linked immunosorbent assay (ELISA) kits. One of the kits 
measured S100A8/S100A9 heterocomplex without cross-reaction to monomers of 
S100A8 or S100A9 (70;72), and the other kit detected S100A9 without cross-
reaction to S100A8/S100A9 heterocomplex. The publication of the study was 
followed by a correspondence regarding the quantification of S100A8, S100A9 and 
complexes of these proteins (72). The research group with Foell, Roth and colleagues 
discussed the possibility of pitfalls in detection of S100 proteins in patient samples 
related to the complex formation in vivo and in vitro (72). Some of the questions 
raised where: 1) Do the protein standards in vitro form the same heterocomplexes as 
the relevant heterocomplex in vivo when recombinant S100A8 and S100A9 are used? 
2) Have the various antibodies used been characterized with respect to specificity and 
affinity to their epitopes? 3) Can the quantification of S100- proteins in one ELISA 
kit be compared to quantification in another ELISA kit in the absence of a “gold 
standard” to which both kits have been calibrated?  
Similar questions apply to published results of S100A12 quantification in two 
different ELISAs developed by independent research groups (73;74). S100A12 was 
found in increased amount quantified by ELISA in serum from Kawasaki vasculitis’ 
patients (75;76), and in rheumatoid, juvenile and psoriatic arthritis’ patients (73;77). 
Another research group found higher concentrations in EDTA plasma in patients with 
diabetes mellitus type 2 than in healthy controls (74). However, none of these two 
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groups examined the possible influences on the estimated concentration from 
collection tube anticoagulants (EDTA plasma), time delays in clinical routine, 
laboratory handling or other aspects that might be important for reliable results. With 
respect to calprotectin, EDTA plasma was recommended due to stability before 
separation of plasma or serum from the blood sample (78). Serum concentrations 
were about twice as high as plasma. The in vitro increase of calprotectin in 
conjunction with coagulation was regarded as interfering with the interpretation of 
the circulating calprotectin concentration (78). As mentioned above, commercially 
available ELISA kits for S100A8, S100A9, the complex of these or the native protein 
calprotectin, are based on various standards and antibodies, which may affect 
research results and interpretations (72). The quantification of calprotectin developed 
in Oslo, is based on calprotectin purified from human granulocytes as standard, and 
polyclonal antibodies raised in rabbits against this standard (4;12;15;78-80). The 
published ELISAs for S100A12 were developed as rabbit polyclonal antibodies to 
S100A12 purified from human granulocytes (73) or with two mouse monoclonal 
antibodies against recombinant S100A12 (74). The concentrations published for 
S100A12 from these two research groups have not been calibrated against each other 
or an international standard. Furthermore, it is possible that conformational changes 
of S100A12 in vitro might apply to the protein in blood, in a manner that affects the 
antigenic epitopes and thus the interaction with certain antibodies used in ELISAs. 
With a homology of amino acid sequences in S100A8, S100A9 and S100A12 of 
about 40-70% (55), a rabbit polyclonal antibody raised against S100A8 was found to 
cross-react with S100A9 and S100A12 (p6) (46).  
Quantification of S100 proteins in ELISAs depend on specific antibodies to interact 
with epitopes that might be changed during sampling or analysis, thus the method is 
dependent on conditions that preserves the three-dimensional conformation of the 
protein for a reliable result. Mass spectrometric (MS) examination of proteins is a 
technique that could allow a large number of samples of blood or other body fluids to 
be analyzed for many proteins in a short time (81;82). The editorial of Clinical 
Chemistry described MS-based diagnostic as “the upcoming revolution in disease 
 25
detection” (82). The quantification of biomarker proteins using MS might be a useful 
diagnostic tool in the future. For the time being, MS techniques are used to discover 
proteins that could serve as biomarkers, e.g. in RA (83;84). S100A8, S100A9 and 
S100A12 were found as candidate biomarkers in synovial fluid and serum from RA 
patients (83;84). Serum concentrations of S100A8, S100A9 and S100A12 were 
found to be 6-fold, 14-fold and 111-fold higher, respectively, in patients with erosive 
RA than in healthy controls (84). MS quantification of pooled serum samples from 15 
healthy controls showed a concentration of S100A12 of 5.3 ng/ml (µg/L) while the 
15 patients with erosive RA had from 38 to 80 ng/ml in three different experiments 
with the pools of sera. The same MS quantification was used to estimate CRP, and 
compared this to quantification with immunoassay. The results showed significant 
discrepancies in concentrations measured by the two methods with the immunoassay 
most often estimating higher concentrations than MS. However, the ratios between 
healthy controls and RA patients were comparable for MS and immunoassay 
quantification of CRP (84).  
 
 
1.3 Lipids as biochemimical indicators and therapeutic 
tools 
The activation of leukocytes during an inflammatory response leads to de novo 
synthesis and release of cytokines, lipid mediators, enzymes and biogenic amines 
(e.g. histamines) (1). Lipid-derived mediators have a variety of effects on leukocytes, 
blood vessels and other tissues. Two important groups of such mediators are 
prostaglandins (PGs) and leukotrienes, collectively called eicosanoids (1;85). They 
are derived from the fatty acids (FAs) via the cyclooxygenase or lipoxygenase 
pathways, most often from the 20-carbon long polyunsaturated FA (PUFA) 
arachidonic acid (AA) since this is the most abundant FA in inflammatory cells (85-
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87). The omega (denoted ω or n) nomenclature indicates on which carbon the first 
double binding in unsaturated FAs occurs, counting from the methyl end of the FA. 
In general, n-6 FAs like AA are abundant in the Western diet, whereas n-3 FAs are 
scarce, but found in seal, oily fish and concentrated oils from such sources (87). The 
overall effect on inflammation of eicosanoids depends on which cells are involved, 
the nature of the stimulus, concentration of the different eicosanoids generated and 
the sensitivity of the target cells and tissues. In such a complex interplay, PGE2 may 
have either pro- or anti-inflammatory effects (85;87). There are indications, but not 
clear evidence, that the eicosanoid mediators derived from eicosapentaenoic acid 
(EPA) and other n-3 PUFAs have less potent pro-inflammatory effects, or even 
possess anti-inflammatory effects compared to eicosanoids derived from AA (87). 
Increased dietary intake of EPA and other n-3 PUFAs affected the FA composition of 
human inflammatory cells in a dose-dependent fashion with alterations in 
concentrations of eicosanoids (reviewed in (87)). Measurements of eicosanoids may 
be useful as biomarkers indicating the inflammatory state of the organ/system in 
question (87-89). The double bonds in PUFAs are susceptible to lipid oxidation, and 
reactive oxygen species (ROS) may initiate a chain reaction of lipid peroxidation 
(85;87;90). Antioxidants vitamins A, C and E, zinc and other substances can interrupt 
these reactions during initiation or propagation stages (90). The lipid antioxidant 
vitamin E is particularly important in the protection of PUFAs. Lipid peroxidation is 
often assesed by measuring thiobarbituric acid reactive substances (TBARS) (90).  
 
In two clinical studies where IBD patients were given seal oil enterally by a 
nasoduodenal feeding tube for 10 days, IBD disease activity, joint pain index, serum 
cholesterol level and the rectal mucosa biopsies’ n-6/n-3 ratio were significantly 
decreased (86;91). Compared to rectal biopsies from a control group without 
inflammatory reactions in the mucosa, the amount of PUFAs (given as the ratio of n-
6/n-3) indicated a shift towards a normal ratio after treatment with seal oil (from 
mean ratio 6.6 to 2.2) (86;91). Only weak evidence supported the hypothesis that n-3 
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PUFAs supplementation from fish oil preparations could be beneficial in IBD in 13 
clinical studies reviewed by Calder (87).  
Radiotherapy (RT) induced proctitis may have some similarities to IBD 
microscopically, endoscopically and clinically (92;93), and such common features led 
to the hypothesis that knowledge from IBD studies might be applicable in RT 
induced proctitis. Biopsies from rectal mucosa in patients about to receive RT for 
prostate cancer were analyzed for FAs (published in a thesis for master degree in 
nutrition (94)). Ten patients were examined within days before start of RT, during 
and after RT (a total of five examinations). The results indicated a shift in the 
composition of FAs as radiation dose increased, with significantly more n-6 PUFAs 
and less n-3 PUFAs in the biopsies taken nine weeks after RT. Three and nine weeks 
after completed RT a significant increase of eicosatrien acid (mead acid, 20:3 n-9) 
was found, indicating a deficiency of essential FAs (94).  
Dietary interventions aimed at reducing the risk of developing cancer in a healthy 
person is a different situation from two closely related topics: protection of normal 
tissue that is about to be exposed to RT versus protection of the malignant cells that 
preferentially should be susceptible to RT. Finally, treatment of late RT effects in a 
cured cancer patient is yet a separate topic, as there presumably should be no need to 
consider tumour cells. 
In the above referred study (94), the FAs in normal rectal mucosa were studied 
before, during and after the oxidative stress generated by the RT. The response to RT 
of normal tissue may be different from that of malignant cells. In vitro studies of 
effects on cancer cells showed that fewer colorectal adenocarcinoma cells survived if 
they were incubated with n-3 PUFAs prior to the single radiotherapy exposure (95). 
There were indications that n-3 PUFAs induced apoptosis in these experiments also 
without the radiation. If the cells were incubated with vitamin E and n-3 PUFAs 
before radiation, the increased cell death due to n-3 PUFAs was abolished (95). The 
authors therefore suggested that lipid peroxidation was involved in the antitumor 
properties of PUFAs. Comparable results and interpretation were found using a rat 
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model with induced mammary cancer (96). The rats were divided into three groups 
before a single radiation exposure: a control group, a group that were fed a diet with 
high n-3 PUFAs content and a group fed with high n-3 PUFAs content plus vitamin 
E. Tumor sizes were more reduced in the group fed with high n-3 PUFAs (60% 
reduction in tumor size) than in the control group (31%), with the combined n-3 
PUFAs and vitamin E closer to the control group (36% reduction in tumor size) (96). 
A third research group found similar results with pancreatic cancer cell lines and a 
leukaemic cell line (97). They examined not only effects of radiation, PUFAs and 
vitamin E, but also how the timing of radiation and incubation with PUFAs 
influenced cell survival (97). In the publications from Benais-Pont and colleagues 
(95) cells were incubated with PUFAs before radiation, while Hawkins and 
colleagues found that more pancreatic cells died if incubated with PUFAs after the 
radiation rather than before or simultaneously with the radiation (97). In 1966 a paper 
described the enhanced effect of radiation by adding a compound that increased the 
amount of ROS in the cancer cell culture (98). At the 40-years anniversary of this 
journal, the editorial board chose this and six papers from the first issues to be 
reprinted and commented (99-101). The principle of enhancing anti-tumor effect by 
generating ROS is re-emerging in cancer research today (100;102). The complex 
protein cellular signalling systems recognise radiation-induced oxidative damage to 
DNA and plasma membrane lipids (102). This leads in turn to stimulation of 
intracellular signalling pathways, which modulate the activity of genes controlling 
apoptosis, cell-cycle arrest or repair of damaged molecules including DNA (102). 
Apoptosis can be initiated if the cellular membrane has been damaged by radiation 
and a second messenger for this signalling pathway is ceramide (102-104). Ceramide 
can be synthesized de novo or generated by enzymatic hydrolysis of 
sphingomyelinase from sphingomyelin, which is the major membrane sphingolipid 
(102;104). Radiation activates sphingomyelinase (102;103), and modulation of 
ceramide signalling might be useful for enhancement of RT effects. 
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 Studies on the effects of a FA analogue (tetradecylthioacetic acid, TTA) in cell 
cultures showed that it induced apoptosis in malignant cells (glioma and leukaemia 
cells) as well as in normal T-cells (105;106).  
As to date, supplementation of PUFAs in conjunction with oncological treatment 
seems rather to enhance cell killing than protect tumor cells (95;97;107). However, 
the above referred experiments with cells or animals still differ greatly from RT of 
patients using fractionated radiation. Concerning the normal tissues, Wen and 
colleagues studied oral mucosa reactions of radiation in mice and tumor effect in 
nude mice (107). They showed protection of mucosal radiation effects from 
injections with n-3 PUFAs. Inhibition of tumor growth was seen with n-3 PUFAs 
injections as the sole treatment, but maximal effect observed when PUFAs and 
radiation were combined (107).  
It might not be advisable to administer vitamin E in conjunction with oncological 
treatment until the effects on tumor growth have been thoroughly studied. However, 
as a potent chain-breaker of unwanted lipid peroxidation, the use of vitamin E might 
be appropriate after completion of oncological treatment. Dietary interventions after 
RT was reported in 17 studies (108). The authors concluded that evidence was 
limited, but antioxidant supplementation might be useful (108).  
 
1.4 Acute radiation proctitis 
Radiotherapy (RT) is the main oncological treatment modality for many cancer 
patients (109-111). Estimates show that 20% to 50% of patients with pelvic cancers 
undergo RT (110;112) and up to 50% of patients with abdominal or pelvic cancers 
may have RT as part of their treatment (111). This gives estimates of 11 000-12 000 
new patients treated each year in United Kingdom (110). Taking in account that half 
of survivors might suffer some degree of bowel dysfunction after abdominopelvic 
RT, more than 1 million patients in the USA may suffer from RT sequelae (111). In 
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Norway, 3818 new cases of prostate cancer were diagnosed in 2004 (113), 1137 
rectal cancers and around 1000 other abdominopelvic cancers. Conservative 
estimates of patients treated with abdominopelvic RT would be about 2000 each year. 
Major technological improvements in radiation treatment planning and delivery have 
allowed increased doses given to the tumour while reducing the dose to normal 
tissues in neighbouring locations (fig. 4). However, generally the tumour dose is 
increased to obtain better tumour control while the normal tissues are irradiated at the 
same dose level, albeit in smaller volumes (114). Studies have shown that increased 
dose per fraction, higher total RT dose and reduced overall treatment time increased 
the severity and frequency of late radiation enteropathy in a rat model (115;116). 
However, much research remains to elucidate why some patients develop late 
radiation enteropathy. The prevalence of moderate to severe late bowel effects (three 
months after completion of RT) varies from 5% to above 30% (113;117-121). 
Clinical studies have shown that the risk of developing late radiation enteropathy 
increases if gastrointestinal symptoms of acute radiation enteropathy were present 
during RT (118;120-125). The processes start during the course of RT, and analyzing 
for changes induced by RT during the acute phase is a step toward understanding the 
chronic, progressive enteropathy that might ensue. 
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4A)  
 
 
4B) 
Figure 4. Conformal radiotherapy of pelvic region 
A) Computer tomography planned four-field RT. Transversal section in height with hips, 
supine position. Red line in centre indicate clinical target volume (cervical cancer), to 
receive 100% of RT dose, dark blue lined delineate expected 30% of RT dose in these 
areas.  
B) Three-dimensional illustration of prostate with seminal vesicles, clinical target volume by 
treatment of prostate cancer (red organ), urinary bladder (yellow organ) and rectum (green 
organ) visualised from the left side view of the patient (Helax-model patient in lower left 
corner). Yellow lines: multileaf collimator delineating the RT field borders. In the lower right 
corner: Helax-model patient lying on treatment equipment.  
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RT effects are caused by reactive oxygen species (ROS) generated in tissues (109). 
These short-lived substances start chain reactions leading to damage on DNA and 
other molecules like plasma membrane lipids (102;103). Cells are more susceptible at 
some stages during the cell cyclus (G2 and mitosis most sensitive (109)). If the 
damage on the cell and in particular on DNA is irreversible, the cell stops dividing, 
and eventually dies. Most cancer cells divide relatively frequent and are hence more 
often vulnerable to RT. Epithelial cells of intestines have a high proliferation rate and 
are at risk of RT damage. However, death of stem cells in the intestinal crypts is 
probably not the main event leading to radiation-induced late effects rather it is a 
consequence of apoptosis of endothelial cells of small vessels (126;127).  
The biological changes during RT have been studied in cells and animal models, and 
more recently in humans. Prediction of normal tissue tolerance to RT and 
interventions to alter the sensitivity individually are topics of major concern in 
radiobiology research (109). A model for the clinical normal tissue radiosensitivity 
was proposed in a review (128) taking numerous gene responses into consideration, 
assuming suboptimal function of gene products. This model implies that e.g. 
alterations in DNA repair genes, genes coding for scavengers of ROS, overexpression 
of the gene for tumour growth factor-β1 and other responses to radiation damage may 
combine into the observed individual tolerance for normal tissue complications (128). 
Large-scale and well-planned clinical studies to examine the possibility of predicting 
individual RT complication risk were recommended.  
The physiological environment in the tissues can be influenced e.g. by cessation of 
smoking during RT. Studies in animal models have shown that carbon monoxide 
inhalation (similar to tobacco smoking) protects tumour cells (129), thus a higher 
radiation dose is required to obtain tumour control. The use of objective 
measurements of smoking cessation has been recommended in clinical trials 
evaluating the effect of smoking on survival after RT (130). Dietary interventions 
during RT have been examined in 18 studies reviewed by McGough (108), 
recommending further research with low-fat diets, probiotic supplementation and 
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elemental diets. Transient decrease in nutritional intake and slowly developing 
cobalamin deficiency were recently described in rectal cancer patients during RT 
(131;132). Smoking was the strongest predictor of late radiation complications in 
nearly 3500 cervical cancer patients (117), and differences in diets between the ethnic 
groups was suggested as an explanation to differences in late radiation effects. In 
addition to smoking habits and ethnical relations, body composition were important, 
in that thin women had an increased risk of intestinal complications while obese 
women were more likely to have serious bladder complications (117).  
Time course of gastrointestinal symptoms was not congruent to the histopathological 
grading of inflammation in rectal mucosa (92;93;120). Biopsies are considered “gold 
standard” in defining inflammation. The discrepancy in time course with maximal 
inflammation at first examination after start of RT while symptoms reach their 
maximum towards the end of RT, could have important implications for future 
prophylactic interventions to mitigate acute and late radiation enteropathy. The 
possibility to obtain rectal mucosa biopsies in prostate cancer patients, receiving 
rather homogeneous radiation doses, makes this a feasible clinical model to study 
physiological changes induced by RT. The complexities of the tissue damage and 
repair processes that take place during the weeks of fractionated RT have been 
divided in four categories to better understand the key processes:1) Epithelial injury; 
2) Inflammation; 3) Endothelial cell changes and activation of the coagulation 
system; and 4) Proliferation and repair (133).  
Gastrointestinal symptoms like diarrhoea, blood on stools and abdominal pains are 
shared by radiation enteropathy and IBD. In the case of radiation enteropathy, the 
initiating event of the ensuing inflammation is the repeated generation of ROS. A 
natural defence mechanism of the innate immune system is also the generation of 
ROS by leukocytes (1). However, in IBD the ROS produced by leucocytes 
infiltrating in the mucosa destroy tissues and decrease the amount of important 
antioxidants (134). Oral ferrous iron therapy increased oxidative stress in patients 
with IBD assessed by plasma reduced cysteine and reduced glutathione (135). Lipid 
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peroxidation, measured by malondialdehyde in plasma, increased in IBD-patients 
after oral and intravenous iron therapy (136;137). Antioxidant vitamin 
supplementation in Crohn’s disease reduced oxidative stress measured in plasma and 
breath tests (138). Whether such factors relevant in IBD could also be applicable in 
RT remains to be studied. Obviously, the deleterious effect on cancer cells must not 
be compromised by interventions aimed at reducing normal tissue late radiation 
effects. There are controversies regarding the use of antioxidant supplements while 
the tumour is still untreated (139).  
 
 
1.5 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation 
of the synovium of joints and destruction of the cartilage and bone. The diagnosis is 
mainly clinical, based on criteria from the American College of Rheumatology, 
revised in 1987 (85). Four of seven criteria must be demonstrated in the patient, and 
have a duration of more than six weeks. One criterion is radiographic changes and the 
only laboratory criterion included is the finding of serum rheumatoid factor (RF). 
Interpreted together with the clinical picture, RF may support a diagnosis of RA. 
However, finding of RF in serum does not exclude other related diseases, and RF is 
found in 5% of the normal population (140). Approximately 10% of RA patients will 
remain RF negative (140). In a study examining gene expression in peripheral blood 
mononuclear cells from RA patients and healthy controls, the RF positive and RF 
negative patients could not be discriminated, while RA patients and healthy controls 
could (69). RF is hence used in the differential diagnosis of RA but also as a 
prognostic biomarker. During the first half of the twentieth century RF was 
discovered by Erik Waaler (1940, Oslo) and later Harry M. Rose and Charles A. 
Ragan (1948, New York) (85;141). Waaler recollects how his observations of “the 
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factor, which was a globulin, reacted as an antibody with another globulin. This other 
globulin was an antibody, which behaved as if it were an antigen” (141). At the time 
his finding seemed “remarkable, even improbable” (141). The laboratory techniques 
applied have changed since then, but RF remains important in rheumatology 
(85;140;142). High levels of serum RF are associated with a worse prognosis in RA 
(140). Waaler or Latex tests mainly identify RF of IgM class of immunoglobulins 
(Ig). Using ELISAs for detection of IgM, IgG, IgE or IgA type RFs, discriminative 
functions of the subtypes of RFs indicate that IgG RF is a risk factor for development 
of vasculitis, while IgA RF may correlate with vasculitis, bone erosions and a more 
severe disease course (140). Lately another biomarker, anti-cyclic citrullinated 
peptide antibody (anti-CCP antibody) has been found useful in combination with RF 
both in differential diagnosis and prognosis of RA (143;144). Both sensitivity and 
specificity were improved by combining the two biomarkers. The first description of 
autoantibodies against citrullinated peptides came in 1964 (144). Although easily 
applicable in routine use by commercial ELISA kits, its role in rheumatology is not 
yet clearly established.   
The chronic, systemic inflammation in RA is thought to participate in the 
development of atherosclerosis of RA patients, contributing to their higher morbidity 
and mortality (145-148). The reduced long term survival was related to 
cardiovascular (CV) disease in females and malignant diseases in men in a 
Norwegian study of 147 RA patients (147). After correlating for established risk 
factors for CV disease, RA disease duration, higher deformed joint count and 
increased ESR and CRP remained associated with an increased likelihood of carotid 
plaque in 631 RA patients (145). Another study found that disease duration predicted 
serious atherosclerotic plaques while methotrexate appeared to be protective on 
atherosclerosis development (149). In RA patients the chronic inflammation may 
contribute independently or synergistically with atherosclerotic risk factors (smoking, 
hypertension, diabetes and hypercholesterolemia) (148). The premature 
atherosclerosis in RA patients has been referred to as “accelerated atherosclerosis” 
and was suggested as an extra-articular feature of RA (ExRA) (148). Although 
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atherosclerosis is considered an inflammatory disease (150;151), the 
histopathological and pathogenetic mechanisms in the heterogenous group of clinical 
syndromes collectively called systemic vasculitides are a different disease entity, 
thought to be mediated by circulating immune complexes (85).  
The acute phase reaction (measured by ESR and CRP) is commonly used to monitor 
RA disease activity and response to therapy, but intercurrent diseases may complicate 
the interpretation of elevated ESR and CRP. Furthermore, RA patients often have 
CRP in the range of 30-40 mg/L when disease activity is moderate (152). “High-
sensitivity” CRP assays detecting concentrations below 1 mg/L have been found to 
predict CV disease risk in apparently healthy individuals (150;153).  In RA patients 
this is unlikely to be helpful as a screening for CV disease. 
Calprotectin was found in high concentrations in synovial fluid in RA patients 
(17;154). Calprotectin levels in blood samples correlated with RA disease activity but 
their prognostic value remains to be defined (155-157). They may be useful with 
regard to radiological changes of joint destruction (158). Peripheral blood cell gene 
expression profiles showed S100A8, S100A9 and S100A12 to have higher 
expression in RA patients than healthy controls (69). Another study of peripheral 
blood cell gene expression profiles found that out of 4 500 genes expressed, 81 genes 
were expressed differently in RA patients than healthy controls (68). In a logistic 
regression analysis of each gene’s ability to classify samples (patients versus 
controls), S100A12 were among the four best (68). S100A12 was found in synovial 
fluid from RA patients (45;73) and serum concentrations of S100A12 correlated with 
disease activity in RA (67;73).  
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2. Aims of the study 
The overall objective of the present study was to evaluate biomarkers calprotectin 
and S100A12 in two diseases characterized by inflammatory reactions. 
The specific aims of the study were: 
Search for candidate biomarkers that mirror disease activity in acute radiation 
proctitis in samples from blood, stools and/or mucosal biopsies (Paper I and III). 
Describe changes occurring during the course of acute radiation proctitis in clinical 
parameters, histopathological graded inflammation in rectal mucosa biopsies and 
candidate biomarkers. Evaluate their relationship with each other (Paper III).  
Confirm the preliminary results regarding RT induced relative deficiency of essential 
n-3 FAs and plan and execute an interventional study where seal oil should be given 
to prostate cancer patients scheduled for RT (Paper III). 
Develop a reliable method to quantify a new biomarker, S100A12 (Paper II). 
Evaluate serum calprotectin and S100A12 as biomarkers in rheumatoid arthritis, 
specifically how each correlate with other biomarkers, disease activity, extra-articular 
manifestations and concomitant cardiovascular disease (Paper IV).  
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3. Materials and Methods 
3.1 Patients and study design 
Paper I and III included patients consecutively presenting at the outpatient clinic of 
Department of Oncology, Haukeland University Hospital scheduled for conformal 
radiotherapy (RT) for localized prostate cancer. Exclusion criterion was 
gastrointestinal disease. These longitudinal studies examined patients within the week 
before start of RT, two and six weeks into the treatment and (Paper III only) four 
weeks after completion of the RT. Paper II included healthy controls, which in this 
context meant absence of chronic diseases that had been shown or hypothesized to be 
related to increased blood concentrations of calprotectin or S100A12. The healthy 
controls were staff at Haukeland University Hospital. In addition 150 blood donors 
were examined in order to establish a reference range. Paper IV was a cross-sectional 
study of 129 rheumatoid arthritis patients, consecutively included when admitted to 
the out-patient clinic of Department of Rheumatology. 
3.2 Laboratory methods 
Paper II describes the development of an ELISA for S100A12. This was a central 
part of the PhD work, and necessary for the results in Paper III and IV.  
The S100A12 assay was developed in cooperation with Igor B. Bronstein, National 
Institute of Medical Research, London, and Magne K. Fagerhol, Department of 
Immunology and Transfusion Medicine, Ullevaal University Hospital. Recombinant 
S100A12 was provided by Igor B. Bronstein, and the rest of the method developed at 
Ullevaal University Hospital. Polyclonal antibodies were obtained by immunization 
of rabbits with the recombinant S100A12. Immunoaffinity purified anti-S100A12 
was prepared by use of a column where S100A12 had been covalently linked to 
agarose beads. These antibodies were conjugated with alkaline phosphatase (ALP). 
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The IgG-fraction of rabbit anti-S100A12 serum was used for coating of microwell 
plates (MaxiSorp, Nunc, Denmark). Dilutions of the recombinant S100A12 were 
used as standards. For the assay, standards and samples were diluted in tris-buffered 
saline with 10 g/L bovine serum albumin and 0.1 g/L sodium azide as an 
antimicrobial. The first incubation was for two hours and the second, with ALP-
conjugate, for one hour. Between incubations wells were washed four times. Optical 
densities were read at 405 nm after reaction with substrate for about 30 minutes.  
Calprotectin was measured by an ELISA (79), both at Department of Immunology 
and Transfusion Medicine, Ullevaal University Hospital, and Department of 
Immunology and Transfusion Medicine, Haukeland University Hospital.  
S100A12 and calprotectin ELISAs were used to analyze blood samples in Papers II- 
IV as well as stool samples in Paper I and III (only calprotectin in Paper I). 
Stool samples in Papers I and III were additionally analyzed with purchased ELISA-
kits for lactoferrin (IBD-CHEKTM and IBD-SCANTM from TechLab, Blacksburg, 
VA), TNF-α (BIOTRAKTM from Amersham Pharmacia Biotech Limited, 
Buckinghamshire, England), leukotriene B4 (LTB4), prostaglandin E2 (PGE2) and 
tromboxane B2 (R&D Systems Europe, Oxon, England). Transferrin was determined 
by an ELISA very similar to that for calprotectin using reagents prepared at Ullevaal 
University Hospital. α1-antitrypsin was measured by nephelometry using an 
automated instrument from Behring, Germany.  
Routine laboratory methods at Haukeland University Hospital were used for the 
following components in blood: haemoglobin, leukocyte count, platelets, C-reactive 
protein, erythrocyte sedimentation rate (ESR), albumin, creatinin, liver enzymes. 
Rheumatoid factor (RF) was determined by Waaler’s test. Anti-CCP was determined 
in an ELISA assay (QUANTA LiteTM CCP IgG ELISA, INOVA Diagnostics Inc, 
San Diego, CA, USA).  
National Institute of Nutrition and Seafood Research, Bergen, analyzed biopsies and 
blood samples for 37 different fatty acids (FAs), and blood samples were analyzed 
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for LTB4, vitamin E and TBARS. FA composition was determined by a gas liquid 
chromatography (GLC) (159;160). LTB4 was analyzed by ELISA-kits from R&D 
Systems, London, United Kingdom. Vitamin E content (tocopherol isomers α,β,γ,δ)  
was analyzed with high performance liquid chromatography (HPLC) (161). TBARS 
was measured spectrophotometrically (162).  
3.3 Symptoms, diet and histopathology in radiation proctitis 
In Paper III symptoms of gastrointestinal toxicity induced by the radiotherapy was 
recorded with a previously used questionnaire (93) as well as the relevant questions 
from a validated questionnaire, QUWF94 (163). Scores were graded from zero, 
meaning no problem with the item in question, and numbers 1-10, with 10 
representing the most severe of the problem.  
Paper III recorded dietary habits with respect to nutriments rich in potentially 
beneficial fatty acids (fish, nuts and supplements with n-3 FAs), antioxidants (fruit, 
vegetables and micronutriment supplements) and cultured dairy products. The 
questions were “How many days last week did you eat….”.  
Paper III assessed the histopathological inflammation in biopsies from rectal mucosa 
as the radiation dose increased. Nine characteristic features were graded 0-4, with 0 
as normal and 4 for maximal pathology.  
 
3.4 Rheumatoid arthritis’ definitions of disease  
The RA diagnosis was made according to the revised criteria of the American 
College of Rheumatology (formerly, the American Rheumatism Association) (164). 
The investigator’s and the patient’s global assessments of the disease activity and 
pain last week were recorded on a visual analogue scale (VAS). A 28-joint count for 
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tender and swollen joints was performed (165). The composite disease activity score 
DAS28 was calculated (166). The Health Assessment Questionnaire (HAQ) (167) 
was used as functional disability score. Cardiovascular (CV) disease was considered 
present if the patient had been diagnosed with angina pectoris, myocardial infarction 
or congestive heart failure by a cardiologist. Secondary Sjögren’s syndrome was 
considered present if two of three were present: Xerostomia, keratoconjunctivitis 
sicca (reduced tear secretion as measured by Schirmer’s test < 5 mm/5 minutes or a 
positive Rose Bengal test) or serological evidence as positive SS-A, SS-B, RF or 
elevated IgG. Other ExRA were clinically judged based on presence of subcutaneous 
nodules, scleritis or episcleritis, peripheral neuropathy not explained by other 
conditions or pulmonary fibrosis. Felty’s syndrome was defined as splenomegaly and 
persistent neutropenia (<1.5x109). 
 
3.5 Statistics 
In the longitudinal studies (Paper I and III) changes in each parameter (symptom 
scores, biopsy grading) and laboratory measurements were compared to baseline, i.e. 
before start of radiotherapy. The samples sizes of 15 and 20 patients were not 
sufficient to infer how the data were distributed. Non-parametric tests were therefore 
applied, and exact paired permutation tests chosen, since this makes use of the 
magnitude of the measurements, and not only rank order, which is the case with exact 
Wilcoxon paired samples test. Spearman rank order correlations were used to 
compare different parameters at each examination time. 
In Paper II, the sample size of 150 blood donors allowed assumptions of the 
distribution of the concentrations of calprotectin and S100A12 in blood samples. 
After log-transformation, the distributions of both proteins were close to normally 
distributed, compared to the skewed distribution, most pronounced for S100A12, 
before transformation. Hence, we used linear mixed effects models, Pearson 
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correlations or paired-samples t-tests, as appropriate, for log-transformed values. 
Reference intervals for S100A12 and calprotectin for serum, EDTA plasma and 
heparin plasma were calculated separately for each gender as mean ± 2 standard 
deviations on a log scale and transformed back. For S100A12 in serum the influence 
of age and gender was examined using a quadratic regression with possibly different 
relationships for women and men.  
The cross-sectional study and sample size of 129 patients in Paper IV allowed 
regressions between parameters to be explored. Univariate regression between 
variables was analysed. Spearman rank order correlation test was used to compare 
clinical and laboratory variables. The Mann-Whitney test was used to compare 
different subgroups of the patients. Independent associations for extra articular 
rheumatoid arthritis manifestations and concomitant cardiovascular disease were 
examined by multiple logistic regression analyses with a forward stepwise design, 
and odds ratio (OR) and 95% confidences interval (CI) given for any significant 
associations.  
Two-tailed p-values <0.05 were considered statistically significant.  
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4. Summary of results 
4.1 Paper I 
Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a 
pilot study of eight stool markers 
 
The faecal excretion of eight markers of gut inflammation was examined in stool 
samples from 15 patients with prostate cancer scheduled for radiation therapy. Of the 
five proteins only calprotectin and lactoferrin concentrations increased significantly 
during radiation treatment (p=0.0005 and p=0.019). α1-antitrypsin could not be 
detected in any sample and transferrin in nine of 45 samples. No changes during 
treatment were found for TNF-α nor the three eicosanoids PGE2, LTB4 and 
thromboxane B2.  
 
4.2 Paper II 
Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, 
calcium and heparin 
 
Studies of S100A12 in serum, EDTA and heparin plasmata showed that the protein 
was highly influenced by the anticoagulants in vacutainers, calcium concentration in 
buffers and handling of samples. The choice of vacutainer used for drawing blood, 
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the time span before separation of plasma or serum and repeated freeze-thaw cycles 
were all shown to influence the estimated concentration of S100A12 in the ELISA. 
Conformational changes in S100A12 structure and the ability to form dimers and 
oligomers were suggested as the molecular basis of our findings. The hypothesis that 
S100A12 binds to heparin in a fashion that affects the influence of calcium 
concentration was generated on basis of the results. The conformational changes of 
S100A12 in EDTA plasma influenced the ability of our polyclonal antibodies to 
recognize S100A12. Individual S100A12 levels did not change substantially during a 
five week sampling period. Serum was proposed to be the best medium for S100A12 
measurements in patients. Based upon testing of 150 blood donors we suggested 
reference intervals of S100A12 in serum to be 49-1340 µg/L for women and 27-1750 
µg/L for men. The estimated mean concentrations were 234 µg/L in serum samples 
(range 12-15791 µg/L), 114 µg/L (range 3-17282 µg/L) in re-calcified EDTA plasma 
and 48 µg/L (range 2-14843 µg/L) in heparin plasma. 
 
4.3 Paper III 
Time patterns of changes in biomarkers, symptoms and histopathology during 
pelvic radiotherapy 
 
The increase in histopathological inflammation in rectal mucosa biopsies from 20 
prostate cancer patients reached a maximum 2 weeks after start of radiotherapy (RT). 
Symptoms of gastrointestinal toxicity increased with higher radiation dose and had 
not returned to pre-treatment level 4 weeks after RT. Lactoferrin concentrations in 
stools increased significantly in week 6. Significant decreases of vitamin E, leukocyte 
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count, haemoglobin and some groups of fatty acids in blood samples were 
discovered, while a few fatty acids increased significantly during the study period. 
 
4.4 Paper IV 
S100-proteins in rheumatoid arthritis: Calprotectin and S100A12 are associated 
with disease activity, extra-articular manifestations and concomitant 
cardiovascular disease 
 
Serum concentrations of calprotectin and S100A12 were found to correlate 
significantly (p<0.01) with the seven different clinical outcome measurements of RA 
disease activity (DAS28, HAQ etc.) in the 129 patients. Of the clinical indices, 
DAS28 was found to have the most substantial correlation (rho≥0.51) to calprotectin, 
S100A12, ESR and CRP (all p<0.01). Patients with ExRA, positive RF or anti-CCP 
had significantly higher S100A12 levels (p≤0.001) than patients without these 
characteristics. Calprotectin showed a weaker relationship to the same characteristics 
(p=0.06 for the presence of ExRA, p=0.01 and p=0.03 for positive RF and anti-CCP, 
respectively). Logistic regression analyses on ESR, CRP, calprotectin, S100A12, 
anti-CCP and RF titre showed that RF was associated with ExRA (OR 1.19 for each 
titre step, CI 1.03-1.37) and S100A12 was associated with a diagnosis of 
cardiovascular disease (OR 1.055, CI 1.011-1.101). Concentrations of calprotectin 
and S100A12 did not correlate with age, disease duration, gender or current treatment 
with disease-modifying antirheumatic drugs or peroral steroids.  
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5. General discussion 
5.1 Calprotectin and S100A12 
Calprotectin and S100A12 as biomarkers in stools and blood during RT 
Calprotectin has been found useful as a biomarker in stool and blood samples in 
many diseases, particularly those characterized by inflammation (44;59). Paper I 
indicated that fecal calprotectin could be a clinical, objective marker to monitor 
gastrointestinal toxicity during RT. Even though the patients and RT were 
comparable in Papers I and III, as were the stools collection and analysis, we could 
not confirm the increase in fecal calprotectin as the radiation doses were increasing. 
In IBD, both the extent and intensity of inflammation in the bowel are of greater 
magnitude than those after abdominal or pelvic RT. During relapses of IBD fecal 
calprotectin generally increase 10- to 20-fold (5;80;168). Patients with prostate 
cancer receive a RT field with a relatively small volume of intestines included, while 
some other patient groups (gynaecological cancers, bladder cancers, testicular 
cancers, colorectal cancers) usually need larger RT fields to cover tumour and lymph 
node areas. They are consequently more prone to suffer from gastrointestinal toxicity 
during RT. In Paper III we examined S100A12 in stool samples. Concentrations 
were low, and the indications suggesting S100A12 to be considerably less stable than 
calprotectin, lead us to recommend using calprotectin rather than encourage further 
studies on the quantification of S100A12 in stools. Neither calprotectin nor S100A12 
in blood or stools showed major changes during RT.  
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Protein conformational state and consequences for the quantification of S100A12 in 
clinical use 
In Paper II  the newly developed ELISA for quantification of S100A12 showed that 
the concentration of S100A12 increased in EDTA plasma if collection tubes were left 
before separation of plasma; by contrast, serum from blood in gel tubes had stable 
concentrations independent of when separation took place, examined up to 48 hours 
after blood was drawn. Repeated freeze/thaw cycles did not influence S100A12 
concentrations in most of the sera, but for a few individuals’ samples, both 
freeze/thaw cycles and storage in 4˚C increased the measured concentrations of 
S100A12. Leaving sera at room temperature increased the concentrations; similarly 
addition of calcium to the assay buffer gave significantly higher readings. These 
observations were interpreted in the light of a limitation of the ELISA technique 
combined with knowledge from crystallization experiments of S100A12 (54) and our 
own gel permeation chromatography findings. We suggest that the increased 
concentrations observed in serum samples could be explained by formation of larger 
complexes of S100A12, and that such complexes falsely are quantified as if more 
S100A12 are present in the serum sample. We also concluded that the antibody or 
antibodies present in our ELISA depends on the formation of dimers or larger 
complexes of S100A12 to be present in the sample, and that epitopes on the 
conformational state found in EDTA plasma hardly can be detected by the developed 
ELISA.  
 
Paper II  included comparisons between calprotectin and S100A12 regarding 
stability during blood sampling and analysis. Some of the new data regarding 
calprotectin was not published and is described here. Calprotectin concentrations 
were unchanged when serum from blood stored in gel coated tubes (p=0.64) or 
plasma from heparinized blood (p=0.11) were harvested after 24 hours delay, while 
the concentration in EDTA blood increased significantly (mean 1.4 and 2.3 mg/L at 1 
and 24 hours, respectively, p=0.018). In clinical studies, 2 hours has been the time 
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span accepted before separation of plasma. Calprotectin estimates in serum and 
plasma were unaffected by Ca2+- concentration in dilution buffers from 0 to final 
concentrations of about 6 and 21 mM (all p≥0.35). Calprotectin concentrations in 
serum were not significantly changed by ten freeze/ thaw cycles to -20ºC (means 1.4 
and 1.5, range 1.2-1.8 mg/L, p=0.35) or to -70ºC (means 2.3 and 2.2, range 1.6-3.0 
mg/L, p=0.40). Calprotectin concentrations in EDTA plasma decreased when stored 
at room-temperature for three weeks (means 2.1 and 1.5, range 0.9-2.8 mg/L, 
p=0.033). Eleven healthy volunteers were examined seven times during five 
consecutive weeks, samples taken after breakfast and before noon. There was no 
significant change by time in EDTA plasma (p=0.69) during the time period of the 
experiment (fig. 5). The standard deviation for within-individual variation was 0.33 
(95% CI 0.29 – 0.37). Calprotectin serum and plasma concentrations were elevated in 
one individual probably related to bronchitis. Three other serum samples were 
elevated for unknown reasons. All S100A12 concentrations were within the 
suggested reference intervals (S100A12 data in Paper II). 
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Figure 5. Concentrations of calprotectin during five weeks 
Variation in eleven healthy volunteers’ samples (seven examinations in five weeks). Lines 
represent separate volunteers.  
Figure made by Tore Wentzel-Larsen in R software. Printed with kind permission. 
 
Due to our findings in Paper II we have indications that our polyclonal rabbit 
antibodies were either mainly from one clone, possibly also from other clones which 
produce antibodies against epitopes only found when dimers or oligomers of 
S100A12 are present. The consequence of this assumption is that we consider the 
conformational changes of S100A12 in EDTA plasma to be of such a nature that our 
antibody can not estimate the concentration of S100A12 in plasma samples. 
However, when the plasma samples were diluted in a buffer containing calcium, and 
the molarity exceeded the 4 millimols bound by EDTA in the collection tube, 
S100A12 could be quantified also in EDTA plasma samples. This raised a new 
question: at which concentration of calcium can we expect S100A12 to be found in 
the concentration present in the blood of the patient? Both serum and EDTA plasma 
samples had seemingly higher estimated concentrations of S100A12 if more calcium 
(above physiological concentrations, i.e. 2 mM in blood circulation) were added in 
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dilution buffers before quantification. For the estimation of reference intervals, 6 mM 
calcium was arbitrarily chosen based on the 4 mM calcium bound by EDTA and the 2 
mM in circulation. The assay developed in Paper II is hence not satisfactorily for 
future quantification of EDTA samples; this would require antibodies directed at 
epitopes found also on S100A12 in EDTA samples, i.e. independent of calcium 
concentration in the sample.  
EDTA samples from long distance runners showed a 20-fold increase in calprotectin 
concentration (63). Five healthy persons (age 32-55 years) were examined before and 
after an endurance cross-country run of 30 km. The examination times were: 1- 12 
hours before start, immediately (within 10 minutes) after the race and 6 h, 18 h, 48 h 
and 72 h after the race. EDTA blood was drawn and transported on ice to laboratory 
for centrifugation within two hours. The plasmas were frozen at -50ºC. When the 
assay for quantification of S100A12 was developed, the runners gave their consent to 
examination of their samples. We choose to estimate S100A12 even though some 
uncertainties exists regarding the concentration due to EDTA and the subsequent 
addition of calcium in dilution buffers, and the samples also inadvertently had been 
thawed and stored in room temperature for three weeks before freezing and storage at 
-20ºC before the S100A12 analysis. For these reasons, the results are unpublished, 
but may give indications for future research on S100A12. As shown in fig. 6, 
S100A12 in re-calcified EDTA-plasma increased 77-fold from before (mean 358 
µg/L) until immediately after (mean 27 642 µg/L) (p<0.001) a 30 km cross country 
running competition. Based upon the rate of decrease towards the normal after the 
run, an estimated half time in the circulation was 3.1 hours (CI 2.1-5.5), compared to 
about five hours for calprotectin (63) . This half-life estimate was calculated based on 
a linear mixed effect model, as ln(0.5) divided by the estimated slope in the cross-
country run data. Neutrophil counts increased 3.2-fold from 4.0·109 to12.8·109 cells/l 
during the run and had normalized 18 hours after the finish (63). We speculate that 
the much higher increase in S100A12 concentration compared to the increase in 
neutrophil count could indicate active release of S100A12, possibly also leakage if 
neutrophils are crushed in the soles of the feet. However, considering the higher 
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content of calprotectin compared to S100A12 in each neutrophil cell, active release of 
S100A12 seems more likely to explain the increased S100A12 concentration. The 
physiological reason for this may be related to endothelial damage during exhaustive 
physical exercise and involvement of neutrophils in the removal of microthrombi, re-
establishement of a smooth endothelial surface, i.e. inflammation and tissue repair. 
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Figure 6. S100A12 in EDTA plasma before and after 30 km 
cross-country running 
(before the start of the run is marked by -2) 
Figure made by Tore Wentzel-Larsen in R software. Printed with kind permission. 
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Binding between heparin and calprotectin and S100A12 
Heparin and heparan sulphate are linear carbohydrates belonging to the group of 
glycosaminoglycans (GAG). One of the functions of heparan sulphate is mediated 
from the endothelial cell, where it is bound and participate in the recruitment of 
leukocytes to the site of inflammation in tissues (1;169). Two studies have described 
S100A9 and the S100A8/A9 complex binding to endothelial cells by binding to 
heparan sulphate structures of endothelial cell surface glycosaminoglycans (37;58). 
Both these research groups have proposed a role for these proteins in reducing 
oxidative damage to the endothelial cells. Heparin binds to many proteins, and most 
likely also to S100A12, due to its homology with calprotectin (51;55). When 
analyzing serum from gel coated tubes after addition of calcium, S100A12 
concentrations were significantly higher than without adding calcium (Paper II). 
However, in heparin plasma addition of calcium did not change S100A12 estimates. 
This may suggest that the binding of heparin interferes with the calcium induced 
conformational changes of S100A12. In order to examine the influence of heparin as 
an anticoagulant in collection tubes, serum samples were added either heparin-coated 
sepharose beads (HI Trap Heparin, Pharmacia AB, Uppsala, Sweden) or native 
sepharose beads and incubated overnight on a rotator. Supernatants were collected 
and assayed for S100A12 and calprotectin. Some of the supernatants were 
subsequently exposed to new heparin-coated beads for a second overnight incubation 
and assayed for calprotectin. The experiment (partly unpublished data) showed that 
incubation of serum with heparin-coated sepharose beads reduced the S100A12 
concentration significantly from 579 µg/L (incubated with beads without heparin) to 
15µg/L (p<0.001). The calprotectin concentration did not change. However, after a 
second incubation with new heparin-coated beads, calprotectin concentration were 
reduced (mean 2.1 mg/L after first incubation, 0.4 mg/L after second incubation, 
p<0.001). We concluded that S100A12 binds to heparin, and this may support our 
hypothesis on the lack of conformational changes when calcium was added to heparin 
plasma. This indicates that S100A12 has a higher affinity to heparin when compared 
to calprotectin under the conditions in serum.  
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Reference ranges for calprotectin and S100A12 was suggested, based upon 
quantification of the two proteins in three different types of collection tubes from 
each of 150 blood donors. Our recommendation in Paper II is that serum samples 
should be used for S100A12. Considering the stability of calprotectin in serum 
samples, the reference intervals for calprotectin in serum might also be useful, even 
though calprotectin has previously been recommended to be analysed in EDTA 
plasma (78), based on the in vitro increase during coagulation. 
 
In Paper IV a selection of commonly used biomarkers for inflammation and 
rheumatoid arthritis were compared to each other and to indices of disease activity. 
The newly developed ELISA for S100A12 was applied, and serum samples were 
used for the estimation of S100A12 and calprotectin. Previously calprotectin has been 
measured in EDTA plasma (154-157). Paper IV showed that calprotectin in serum 
correlated with disease activity, and hence may be used as a biomarker of RA disease 
activity in EDTA plasma or serum. Correlations were comparable to those of CRP. 
The relationship of calprotectin to RF and ExRA were slightly less significant than 
that of S100A12, and may be indicative of the utility of calprotectin as a marker of 
disease activity rather than a predictive biomarker. This is in line with previous 
results, showing that calprotectin in plasma did not predict joint destruction in 
subsequent years (157). DAS28 was the clinical scoring system that correlated best to 
the laboratory measurements in Paper IV. This may in part rely on the fact that ESR 
is one of the variables entered into the calculation of this composite disease activity 
score (http://www.umcn.nl/userfiles/other/DAS28_ne.xls).  
The diagnosis of CV disease in this study was only based on information in the 
patients’ records, and the patients were not subjected to any screening or objective 
examination with regard to CV disease. Since CV diseases are considered to develop 
over a long time span, most likely more patients would have been diagnosed with CV 
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disease if subjected to a systematic examination. Even with these reservations, 
logistic regression analysis showed an association of concentration of S100A12 and 
CV disease, while this was not found for ESR, CRP, calprotectin, anti-CCP and RF 
titre. RF positive patients have a more severe disease course, and S100A12 might 
have a role as a predictive biomarker in RA. Previous publications on S100A12, RA 
and disease activity included few patients compared to Paper IV (73), but we 
confirmed the correlation of S100A12 to disease activity. However, correlations were 
better for calprotectin and CRP than ESR and S100A12 (Paper IV). 
 
5.2 Other biomarkers and correlation to disease 
In Paper I our results indicated usefulness of lactoferrin and calprotectin measured in 
stool samples, and these two were therefore also examined in Paper III. Only 
lactoferrin were found to increase with increasing radiation dose in Paper III. The six 
remaining stool markers examined in Paper I, and the new candidate marker 
S100A12, were not found to increase during RT (Paper III).  
By defining biomarkers as clinical applicable measurements, the analysis of FAs in 
rectal mucosa biopsies is a too invasive and troublesome examination to qualify as a 
suitable biomarker. Compared to published ratios of n-6/n-3 PUFAs (86;91), the 
patients examined in Paper III had slightly higher ratio (median 3.6) throughout the 
whole study period than the healthy control group (mean 2.2) and the IBD patients 
after seal oil treatment (mean 2.2). The ratio decreased from 6.6 to 2.2 in the IBD 
patients (86;91) after treatment. We did not find any significant change induced by 
the RT (Paper III), and endoscopic, histological and anamnestic information did not 
indicate that the patients suffered from any inflammatory reactions before RT. 
Although many of the study conditions (selection of patients, RT, biopsy handling 
and analysis) were similar in Paper III and the study by Norlie, (94), we could not 
confirm the results suggesting a deficiency of essential FAs developing during RT. 
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The planned interventional study was therefore postponed, until the scientific basis is 
of such a nature that it is timely to do this. Hypotheses from studies of IBD may not 
be representative of the inflammatory processes in acute proctitis during RT. The 
antioxidant vitamin E was decreased as radiation dose increased in Paper III. This 
could indicate an increased consumption of antioxidants during RT. Administration 
of antioxidants during RT is controversial (139), but our observations might indicate 
that further mapping of nutritional and oxidative status could be warranted during the 
course of RT. 
In the case of interventional studies, it would be preferable to have available 
biomarkers to evaluate the effects in a treated versus a control group of patients. At 
present we have measurement of lactoferrin, and possibly also calprotectin, in stools 
as the most promising of the nine markers examined in this study.  
We found no correlation of clinical scoring systems, histopathological scoring and 
laboratory markers (Paper III). Systems of grading disease activity have been 
developed in many diseases and we applied two questionnaires for acute radiation 
proctitis in prostate cancer patients (93;163). Time profiles of gastrointestinal toxicity 
and histopathological scoring of inflammatory changes showed discrepancy in that 
the biopsies were already at a maximum of inflammation at the first examination after 
start of RT, while symptoms increased during the whole RT period (Paper III). The 
implications of this finding, if confirmed, may be of importance when planning when 
to start interventions to prevent acute radiation proctitis. 
 
 
5.3 Future research 
Our study has shown that calprotectin and S100A12 are promising biomarkers in 
patients with rheumatoid arthritis. As biomarkers of the radiation proctitis during RT 
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stool samples seems most appropriate, with lactoferrin and calprotectin as possible 
biomarkers. Stool samples are non-invasive, acceptable for the patients and possible 
to use in clinical studies. The patient group of prostate cancer patients selected for our 
study had a modest bowel inflammation during RT compared to patients with IBD. 
Future studies should examine fecal lactoferrin and calprotectin in other patient 
groups with the aim of monitoring acute radiation enteritis.  
The reported increase in high-sensitivity CRP during RT (170) and other biomarkers 
in blood indicating oxidative stress, e.g. plasma malondialdehyde, should be 
evaluated in future studies. 
 
Methods for the quantification of S100A12 need to be addressed with the findings of 
our study in mind. We recommend that S100A12 is assayed in serum from blood 
collected in gel coated tubes; samples should be analyzed either before freezing, or 
shortly after thawing (within a day). Further studies should examine the reliability of 
assay results in ELISA after serum storage in 4˚C more than two days, or repeated 
freeze/thaw cycles. The hypothesized conformational changes and oligomerization of 
S100A12 is a potentially caveat for ELISA. Our and other research groups have 
found correlation of S100A12 and disease activity in RA patients. Immunoassays and 
MS should be examined as future quantification methods. With reliable methods 
available, other inflammatory or infectious diseases may benefit from measurements 
of S100A12 in blood.  
Laboratory studies of S100A12 should test whether the oligomerization state of 
S100A12 in blood samples are comparable to the hypothesized hexamer in vitro (54). 
The preliminary data of S100A12 binding to heparin should be characterized. The 
clinical role of S100A12 in inflammation should be examined in various patient 
groups, and the association to CV disease and increase after physical exercise are 
findings relevant for such studies.  
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Dietary needs during RT were addressed by Guren et al (131;132). They found 
decreased cobalamin during and one year after RT for rectal cancer. Future studies 
should aim at identifying specific nutritional needs used as a tool to alter the course 
of normal tissue radiation effects both during and in the long time follow up of 
patients. The discovery of predictive profiles identifying patients at risk of normal 
tissue radiation morbidity requires prospective studies with sufficient number of 
patients followed over many years. Such profiles might be combinations of 
nutritional status with regard to lipids and antioxidant status. 
 
Prediction of disease courses are of interest both before start of RT and for patients 
diagnosed with RA. RF is used as a biomarker predictive of a more serious disease 
course of RA. New therapeutic options with TNF-α-receptor inhibitors might change 
the prognosis for RA patients with respect to destruction of joints. A possible 
usefulness of S100A12 in predicting joint destruction should be studied. Morbidity 
and mortality from ExRA and CV disease might be reflected by S100A12 levels. 
Future clinical studies with rheumatic diseases should incorporate adequate 
measurements and examinations of the patients with regard to CV disease or risk of 
such, in order to correlate this with concentrations of calprotectin and S100A12 in 
blood. 
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6. Conclusions 
Although gastrointestinal symptoms and histopathological inflammation in mucosa 
may share common features in IBD and acute radiation proctitis, the severity and 
extent of acute radiation proctitis is limited compared to IBD, and common 
biomarkers of the two disease states are more likely to be found in stool samples than 
in blood. Fecal lactoferrin and possibly calprotectin seems promising candidate 
biomarkers. 
 
Time profiles during radiation therapy differ when comparing histopathology, 
symptoms, fecal lactoferrin and vitamin E concentrations in blood. This timing might 
be of importance when designing future studies and planning prophylactic 
interventions to mitigate acute radiation proctitis.  
 
Calprotectin and S100A12 both correlate with disease activity of RA. Calprotectin 
can be measured in either serum or plasma samples with the aim of assessing disease 
activity in RA. S100A12 was associated with RF as well as with CV disease. 
Calprotectin might be more useful for monitoring disease activity, while the role of 
S100A12 as a biomarker might be related to prognosis in RA. 
 
S100A12 should be analyzed in serum samples, and preferably analyzed within a 
day, before or after freezing. Neither EDTA nor heparin plasma can be recommended 
for the estimation of S100A12 concentration.  
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Errata 
 
Page 10: Paper IV, second last sentence: "Submitted to The Journal of Rheumatol Sept 2006" has 
been changed to the correct "Submitted to Scand J Rheum Dec 2006" before printing of PhD-
thesis. 
 
Page 39: third and fourth paragraph: " ...stool samples in Paper I and II" has been changed to the 
correct "...stool samples in Paper I and III" before printing of PhD-thesis. 
 
 
 
 

